Health Catalyst Stock News

Health Catalyst, Inc. (NASDAQ:HCAT) CEO Daniel D. Burton sold 36,212 shares of the firms stock in a transaction dated Friday, December 3rd. The shares were sold at an average price of $40.62, for a total transaction of $1,470,931.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available []

Conestoga Capital Advisors LLC lessened its stake in Health Catalyst, Inc. (NASDAQ:HCAT) by 0.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 316,044 shares of the companys stock after selling 2,335 shares during the period. Conestoga Capital Advisors []

Health Catalyst Inc. (NASDAQ:HCAT) concluded the trading at $38.90 on Friday, December 03 with a fall of -9.03% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $42.76 and 5Y monthly beta was reading 0.65 with its price kept floating in the Health Catalyst Inc. (HCAT) Sits On Its Hands At $38.90 Read More »

Health Catalyst, Inc. (NASDAQ:HCAT)s share price gapped down before the market opened on Friday . The stock had previously closed at $42.76, but opened at $41.11. Health Catalyst shares last traded at $40.49, with a volume of 4,924 shares traded. Several equities analysts have recently issued reports on HCAT shares. Zacks Investment Research lowered Health []

Grom Social Enterprises (NASDAQ:GROM) and Health Catalyst (NASDAQ:HCAT) are both computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation. Earnings & Valuation This table compares Grom Social Enterprises and Health Catalyst’s top-line […]

Jefferies Financial Group initiated coverage on shares of Health Catalyst (NASDAQ:HCAT) in a report released on Wednesday morning, The Fly reports. The firm issued a hold rating on the stock. A number of other equities research analysts have also commented on HCAT. BTIG Research assumed coverage on Health Catalyst in a research report on Thursday, []

SALT LAKE CITY, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organization

Wall Street analysts expect that Health Catalyst, Inc. (NASDAQ:HCAT) will post sales of $63.18 million for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates for Health Catalysts earnings, with the highest sales estimate coming in at $63.76 million and the lowest estimate coming in at $62.86 million. Health Catalyst posted []

Equities analysts predict that Health Catalyst, Inc. (NASDAQ:HCAT) will announce earnings of ($0.21) per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Health Catalysts earnings, with the highest EPS estimate coming in at ($0.14) and the lowest estimate coming in at ($0.34). Health Catalyst reported earnings []

Health Catalyst (NASDAQ:HCAT) and Magnite (NASDAQ:MGNI) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk. Profitability This table compares Health Catalyst and Magnites net margins, return on equity and return on []

Zacks Investment Research lowered shares of Health Catalyst (NASDAQ:HCAT) from a hold rating to a sell rating in a research report sent to investors on Tuesday, Zacks.com reports. According to Zacks, Health Catalyst Inc. is a provider of data and analytics technology and services to healthcare organizations. Health Catalyst Inc. is based in Salt Lake []

Goldman Sachs Group Inc. lifted its stake in Health Catalyst, Inc. (NASDAQ:HCAT) by 233.2% in the 2nd quarter, HoldingsChannel reports. The firm owned 101,040 shares of the companys stock after buying an additional 70,712 shares during the quarter. Goldman Sachs Group Inc.s holdings in Health Catalyst were worth $5,609,000 at the end of the most []

Health Catalyst, Inc. (NASDAQ:HCAT) CFO Bryan Truman Hunt sold 957 shares of the businesss stock in a transaction on Friday, November 12th. The stock was sold at an average price of $49.40, for a total value of $47,275.80. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC []

Health Catalyst, Inc. (HCAT) CEO Dan Burton on Q3 2021 Results - Earnings Call Transcript

SALT LAKE CITY, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations,